News » Health
Israel is poised to become the first country outside North America to use a new drug for ALS, amyotrophic lateral sclerosis.
Neopharm, headquartered in Petah Tikva, has signed distribution agreement with Amylyx Pharmaceuticals of Massachusetts to distribute AMX0035 in Israel, Judea and Samaria, and Gaza. The new drug is believed to extend the lives of ALS patients by an average of almost a year, according to the Times of Israel.
The drug is currently only available in the US and Canada, and in a statement from Amylyx announcing the deal with Neophsarm, says it could be an “important step” on the way to a wider distribution of the drug in the Middle East, Europe and Africa.
ALS is a relentlessly progressive and fatal neurodegenerative disease caused by the death of motor neurons in the brain and spinal cord. This leads to deterioration in muscle function, inability to move and speak, respiratory paralysis and eventually death.
Clinical evidence based on research has shown that AMX0035 slows the progression of the disease.
Follow us on Telegram